BCM
EW icon

Beck Capital Management’s Edwards Lifesciences EW Stock Holding History

Beck Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-11,367
Closed -$552K – 106
2018
Q2 		$552K Buy
+11,367
New +$531K 0.27% 63

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Beck Capital Management's EW Position: Q3 2018 in Review

Beck Capital Management sold out of Edwards Lifesciences (EW) in Q3 2018, closing a stake of 11,367 shares — an estimated $552K sold.

Beck Capital Management first reported a position in EW in Q2 2018 and held it in 1 quarter. The position peaked at $552K in Q2 2018. 852 funds tracked by Wall St. Rank hold EW as of Q3 2018.

  • Beck Capital Management reported no remaining Edwards Lifesciences position as of Q3 2018 after selling out during the quarter.
  • Beck Capital Management sold 11,367 Edwards Lifesciences shares in Q3 2018, an estimated $552K.
  • Beck Capital Management first reported a position in Edwards Lifesciences in Q2 2018 and held it in 1 quarter.
  • Beck Capital Management's Edwards Lifesciences position peaked at $552K in Q2 2018.
  • 852 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2018.

Based on Beck Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.